First-Of-Its-Kind Cancer Treatment Helps Save Lives « CBS Los … – CBS Los Angeles
|
First-Of-Its-Kind Cancer Treatment Helps Save Lives « CBS Los …
CBS Los Angeles SANTA MONICA (CBSLA) — An Orange County woman given only months to live is now cancer free, thanks to a one-of-a-kind treatment developed by a Santa … |
EnviroNews (registration) (blog) |
World’s 1st Stem Cell Transplant from Donor to Man’s Eye Shows Promise of Restoring Sight
EnviroNews (registration) (blog) A surgical team at Kobe City Medical Center General Hospital in Japan recently injected 250,000 retinal pigment epithelial (RPE) cellsx into the right eye of a man in his 60s. The cells were derived from donor stem cells stored at Kyoto University. It … |
Madison.com |
3 Things You Didn’t Know About bluebird bio, Inc.
Madison.com Gene–therapy leader bluebird bio (NASDAQ: BLUE) has made waves in the CAR-T space, although it’s still trailing the CAR-T front-runners. But here are three things you might not know about the promising biotech. |
Madison.com |
3 Things You Didn’t Know About bluebird bio, Inc.
Madison.com Gene–therapy leader bluebird bio (NASDAQ: BLUE) has made waves in the CAR-T space, although it’s still trailing the CAR-T front-runners. But here are three things you might not know about the promising biotech. |
|
T cell revival correlates with lung cancer response to PD-1 immunotherapy
Science Daily Monitoring the immune response could potentially help oncologists and patients decide, within just a few weeks of starting immunotherapy drugs, whether to continue with current treatment or combine it with something else. “We are already doing larger … |
Motley Fool |
3 Things You Didn’t Know About bluebird bio, Inc.
Motley Fool Most investors are rightfully focused on Bluebird’s LentiGlobin gene therapy treatment. It offers nice potential in the orphan indication of beta thalassemia, plus a more lucrative indication in sickle-cell disease. But there’s a gene–therapy product … |
Motley Fool |
3 Things You Didn’t Know About bluebird bio, Inc.
Motley Fool Most investors are rightfully focused on Bluebird’s LentiGlobin gene therapy treatment. It offers nice potential in the orphan indication of beta thalassemia, plus a more lucrative indication in sickle-cell disease. But there’s a gene–therapy product … |